Defence Therapeutics Inc. (DTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Defence Therapeutics Inc. (DTC) has a cash flow conversion efficiency ratio of 1.144x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.40 Million ≈ $-1.64 Million USD) by net assets (€-1.22 Million ≈ $-1.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Defence Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DTC current and long-term liabilities for a breakdown of total debt and financial obligations.
Defence Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Defence Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polylite Taiwan Co Ltd
TWO:1813
|
0.109x |
|
Bukit Jalil Global Acquisition 1 Ltd. Ordinary Shares
NASDAQ:BUJA
|
-0.014x |
|
Conifer Holding Inc
NASDAQ:CNFR
|
-0.098x |
|
Seouleaguer Co. Ltd
KQ:043710
|
0.033x |
|
Alpha Microelectronics
TWO:8024
|
-0.018x |
|
Blue Sky Uranium Corp
V:BSK
|
1.543x |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
-0.274x |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
0.035x |
Annual Cash Flow Conversion Efficiency for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Defence Therapeutics Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Defence Therapeutics Inc. (DTC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €-3.58 Million ≈ $-4.19 Million |
€-4.29 Million ≈ $-5.01 Million |
1.196x | +124.47% |
| 2023-06-30 | €1.57 Million ≈ $1.83 Million |
€-7.66 Million ≈ $-8.95 Million |
-4.889x | -131.35% |
| 2022-06-30 | €-387.56K ≈ $-453.10K |
€-6.04 Million ≈ $-7.07 Million |
15.596x | +3837.50% |
| 2021-06-30 | €5.49 Million ≈ $6.41 Million |
€-2.29 Million ≈ $-2.68 Million |
-0.417x | -485.46% |
| 2020-06-30 | €1.86 Million ≈ $2.18 Million |
€-132.83K ≈ $-155.29K |
-0.071x | -- |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more